A pediatric study has established a maximum tolerated dose (MTD) for temsirolimus (Tem) of more than 150 mg/m 2 intravenously/week. A phase I trial was conducted to establish the MTD for Tem in combination with valproic acid (VPA) in children and adolescents with refractory solid tumors. The secondary aims included expression of mammalian target of rapamycin (mTOR) markers on archival tumor tissue; Tem pharmacokinetics; assessment of histone acetylation (HA); and tumor response. Patients were treated with VPA (5 mg/kg orally three times daily) with a target serum level of 75-100 mcg/ml. Tem was started at an initial dose of 60 mg/m 2 /week. Pharmacokinetics and HA measurements were performed during weeks 1 and 5. Two of the first three patients experienced dose-limiting toxicity (grade 3 mucositis). Tem at 35 mg/m 2 /week was found to be tolerable. Peak Tem concentrations were higher in all patients compared with those in previously published reports of single agent Tem. Increases in HA are correlated with VPA levels. All tumor samples expressed mTORC1 and mTORC2. An objective response was observed in one patient (melanoma), whereas transient stable disease was observed in four other patients (spinal cord ependymoma, alveolar soft part sarcoma, medullary thyroid carcinoma, and hepatocellular carcinoma). The MTD of Tem when administered with VPA is considerably lower than when used as a single agent, with mucositis the major doselimiting toxicity. The combination merits further study and may have activity in melanoma. Attention to drug-drug interactions will be important in future multiagent trials including Tem.
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Introduction
Temsirolimus (Tem) is a selective inhibitor of the mammalian target of rapamycin (mTOR), which has shown tolerability and efficacy against a wide range of adult cancers [1] [2] [3] [4] [5] [6] . In adults, mucositis, rash, and asthenia have been the most common dose-limiting toxicities (DLT) at doses up to 250 mg/m 2 [7, 8] . However, doses of 15 mg/m 2 have been found to have biologic activity [8] and 25 mg/week is the dose recommended for the singleagent treatment of advanced clear-cell renal-cell carcinoma according to the US Food and Drug Administrationapproved indication for Tem [9] . Several mTOR inhibitors have shown significant antitumor activity in both in-vitro and in-vivo pediatric solid tumor models, including rhabdomyosarcoma, gliomas, and neuroblastoma [10] [11] [12] . A recent phase I-II study of Tem as a single agent in children found the drug to be tolerable when administered intravenously in doses as high as 150 mg/m 2 /week, with pharmacokinetics (PKs) similar to those seen in adults [13] .
Valproic acid (VPA) is a histone deacetylase (HDAC) inhibitor that has also shown in-vitro and in-vivo antitumor activity against a range of cancers in children [14] [15] [16] . This is a drug that has a long history in pediatrics as an anticonvulsant at target serum levels of 50-100 mcg/ml. In addition to inhibiting HDAC, VPA modulates cell cycle progression, induces tumor apoptosis and differentiation, and inhibits angiogenesis in in-vitro and in-vivo tumor models. VPA inhibits other signaling pathways in addition to HDAC inhibition, including ERK, PKC, and Wnt. However, hyperacetylation of histones H3 and H4 as a result of HDAC inhibition is considered to be the major mechanism of VPA's antitumor activity [17] .
Both mTOR inhibitors and VPA are inducers of autophagy [18, 19] . Our rationale for combining Tem and VPA was based on the apparently minimal and largely nonoverlapping toxicities of each of these drugs as single agents, the long track record of VPA in children, past demonstration of anticancer activity of these drugs as single agents in vitro and in vivo, both different and shared mechanisms of antitumor activity, and our unpublished results of the additive effects of these drugs against neuroblastoma in vitro (D.W. Coulter, personal communication). A recent report using a similar combination in vitro in prostate cancer also suggests that it may have some additive effects [20] . The current report describes our phase I experience with escalating doses of Tem in combination with VPA.
Materials and methods

Patients
Eligibility criteria included male or female patients, 2-18 years of age, with radiographic evidence of a persistent or a progressive histologically verified solid tumor after standard therapy, normal renal, liver, and hematopoietic function using standard criteria (transfusion support was permitted for patients with marrow involvement), and an age-appropriate performance status of at least 50%. Patients must have been off previous cancer-specific treatment for at least 2 weeks and must have recovered from previous toxicities. Current use of anticonvulsants including VPA, or the use of CYP3A4 inducers or inhibitors and drugs that are CYP2D6 substrates were exclusion criteria. Although the intent was to evaluate response on the basis of the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [21] , this requirement was waived for one patient with measurable disease, but with lesions smaller than 10 mm. The study was opened at the University of North Carolina at Chapel Hill in 2009 and at Levine Children's Hospital in 2010. Patients or their legal guardians provided written informed consent approved by the respective institutional review board before study participation.
Pretreatment evaluations included assessment of medical history, physical examination, performance status assessment, a complete blood count with differential, serum electrolytes, renal and liver function tests, fasting cholesterol and triglyceride levels, tumor measurements, and serum or urine pregnancy tests for female participants of childbearing age. Peripheral blood was collected for mononuclear cell isolation (below). Archival tumor tissue was obtained for correlative studies (below). Participation was not dependent on mTOR expression.
Study design
This was an open-label single-arm dose-escalation study of Tem [Pfizer (formerly Wyeth) Pharmaceuticals, Philadelphia, Pennsylvania, USA] in combination with VPA. VPA was commercially available and initiated at a dose of 15 mg/kg/day administered three times daily orally 3-7 days before starting Tem with the intent to achieve trough plasma levels of 75-100 mcg/ml. This dose was selected on the basis of its previous use as a single agent in pediatric cancer patients [16] . Patients were asked to keep daily diaries of VPA use. Tem was administered intravenously over 30-60 min weekly after premedication with diphenhydramine (0.5-1 mg/kg to a maximum dose of 50 mg). After the first patient developed a moderate infusional reaction, Tem was subsequently infused over 60 min without problems. The starting Tem dose was 60 mg/m 2 on the basis of ideal body weight, with the next dose level (dose level-1) of 35 mg/m 2 . Achievement of target VPA levels was not required before the initiation of Tem, and VPA doses were titrated over time on the basis of levels and toxicity (below).
A minimum of three patients assessable for toxicity was planned at each dose level. Patients were considered to have tolerated a given dose level if they had received at least 6 weeks of combination therapy without DLT (defined below). The maximum tolerated dose (MTD) was defined as the dose level immediately below that at which two of six patients experienced DLTs during the first 6 weeks of treatment, and the intent was to treat six evaluable patients at the MTD. There was no intrapatient dose escalation. Patients who experienced a DLT could opt for additional treatment on study at the next lower dose of Tem, or could continue combination treatment off study at every other week intervals and/or at lower Tem doses at the discretion of the family and treating clinician. Patients without DLTs could continue therapy for up to a year or until disease progression.
Evaluation of toxicity
Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.1. Grade 4 thrombocytopenia or neutropenia of more than 7 days in duration was classified as a hematologic DLT for patients without marrow involvement by tumor. Nonhematologic DLTs included all grade 3 or 4 Tem-related toxicities resulting in delay in treatment for more than 2 weeks.
Evaluation of response
Tumor measurements were performed before every fourth month of treatment, in the event of DLT, or if the family elected to come off study after the first 6 weeks. Tumor response was evaluated using RECIST 1.1 [21] . Patients must have been in the study for at least 6 weeks to be evaluable for efficacy.
Pharmacokinetic studies
PK studies to measure Tem levels were carried out during weeks 1 and 5. Whole-blood samples (2 ml) were collected in EDTA-treated tubes before Tem administration and at 0.5, 1, 2, 5, and 24 h after administration. Samples were mixed, transferred into separate polypropylene tubes, and stored at -201C within 60 min of the venipuncture. In all except patient no. 6, PK samples were obtained from a site different from that into which Tem had been administered. Tem concentrations were determined by liquid chromatography/triple quadrupole mass spectrometry (HPLC-MS/MS) using a previously validated method [22] . The HPLC-MS/MS system consisted of two Shimadzu Scientific solvent delivery pumps (Shimadzu Scientific Instruments, Columbia, Maryland, USA), a Valco switching valve (Valco, Houston, Texas, USA), a thermostated (61C) Leap HTC autosampler (Leap Technologies, Carrboro, North Carolina, USA), and an Applied Biosystems API3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, California, USA). Quality controls, also in whole blood, were prepared in triplicate. The lower limit of quantification was 60 ng/ml, with all standards and all controls achieving at least 85% accuracy and precision. A noncompartmental model was fit to the concentration-time data using Phoenix WinNonlin software, version 6.2 (Pharsight Inc., Cary, North Carolina, USA). Individual patient PK profiles and the parameters of area under the concentrationtime curve (AUC) 0-24 h after dose, T max , C max , clearance (CL), volume of distribution (V d ), and half-life were reported using descriptive statistics.
Immunohistochemistry
Slides from diagnostic paraffin-embedded tissue obtained before any chemoradiotherapy were stained with primary rabbit antibodies to Raptor (mTORC1), Rictor (mTORC2), and LC3 (Bethyl Laboratories, Montgomery, Texas, USA). Antibodies were used at a final dilution of 1 : 300 in PBS containing 2% horse serum and applied overnight at 41C. Antibody-antigen complexes were visualized using a Dako EnVision System HRP (DAB) kit (Dako, Carpinteria, California, USA) according to the manufacturer's protocol. Two slides from each sample were reviewed unblinded (B.M.M.S., J.B., S.V.S.) and scored subjectively as negative or positive (weak, intermediate, strong) compared with negative and positive control slides (human lung squamous cell carcinoma without and with the primary antibody).
Histone acetylation measurements
Heparinized blood was obtained from three patients before the initiation of VPA, after 3-7 days of VPA but before the initiation of Tem, and just before the second or fifth Tem dose. Samples were obtained just before the morning dose of VPA.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient centrifugation and stored at -801C. Cell extracts, normalized for PBMC number, were separated by SDS-PAGE, transferred to nitrocellulose, and blotted with rabbit anti-tetra-acetyl H4 (1 : 2000; Active Motif, Carlsbad, California, USA) and rabbit anti-pan-H4 (1 : 1000; Millipore, Billerica, Massachusetts, USA). Western blots were scanned and quantified (Licor Odyssey v. 3.0; Lincoln, Maine, USA).
Results
Seven patients were enrolled in the study over a period of 2 years. One patient died within 2 weeks of starting treatment because of tumor progression and was considered to be nonevaluable. The characteristics of the six evaluable patients are shown in Table 1 .
Toxicity Table 2 summarizes the toxicities observed in patients enrolled in this trial. Grade 3 mucositis was experienced by two of three patients at dose level 1 (60 mg/m 2 ) and was considered to be dose limiting because it did not improve to grade 1 or 2 within 14 days. Both these patients had received radiation therapy in the head and neck region, although in each case, the interval between radiation and Tem was more than a year. Subsequent patients received a decreased Tem dose of 35 mg/m 2 . Even at this lower dose, all patients experienced mucositis limited to grade 1 or 2, with the exception of one patient with grade 3 who did not fulfill the DLT criteria (i.e. the patient recovered within 14 days of treatment and did not require dose or schedule modification of Tem). Other non-DLTs attributed to Tem included acne (n = 1), a grade 3 allergic infusional reaction consisting of fever, chills, and mild hypotension when Tem was administered over 30 min (n = 1), and chest pain (n = 1). Toxicity seemed to correlate with VPA levels greater than 75 mcg/ml. The first three patients also experienced dose-limiting fatigue, which was first noted before initiation of Tem. Because fatigue is a known side effect of VPA, and was identified as a DLT in a phase I study of VPA in pediatric patients with solid tumors [16] , the dose of VPA was reduced in an effort to preserve Tem dosing. Thus, serum levels below the targeted 75-100 mcg/ml were allowed, and grade 3 fatigue rather than serum level was used as the dosing endpoint. One patient developed grade 2 thrombocytopenia at a VPA level of 56 mcg/ml, which resolved after holding VPA for 3 days. Tem was not held and VPA was resumed without a recurrent decrease in platelets. One patient (no. 5) developed grade 3 poorly characterized bilateral plantar pain believed to be because of VPA (which is reported to be a cause of paresthesias), for which both VPA and Tem were suspended for 3 weeks. Because this toxicity was noted at the beginning of the fourth month of treatment and because it was not considered to be attributable to Tem, it was not considered to be a DLT. The VPA level was 87 mcg/ml at the time of maximum symptoms. The patient was restarted on a reduced dose of VPA once the symptoms had almost resolved. The VPA level after 24 h at the reduced dose was 52 mcg/ml and Tem was restarted. Because of slow accrual, the study was discontinued after only three patients had received 35 mg/m 2 . Although it is likely that this is the MTD of Tem when administered in combination with VPA, the limited number of patients treated at this dose raises the possibility that toxicity might have been observed eventually.
Immunohistochemistry
The expression of both mTORC1 and mTORC2 was intermediate or strong in the pretreatment tumor samples in all patients. None of the pretreatment samples expressed LC3.
Tumor response
As summarized in Table 3 , an objective response not fulfilling the criteria for a partial response was observed in one child (no. 3) with progressive metastatic melanoma. After dose-limiting mucositis following 3 weeks at the 60 mg/m 2 dose level, Tem was continued at 35 mg/m 2 . At his family's discretion, he came off the study after 2 months and received treatment every 2 weeks. He showed a 15% reduction in tumor size by the RECIST criteria after 4 months of treatment. However, at his family's discretion, treatment was extended to every 3-4 weeks with a minimal increase in tumor size 2 months later and he came off treatment. He had clear progressive disease 12 months from the start of Tem/VPA. Two other patients treated at 60 mg/m 2 [alveolar soft part sarcoma (n = 1) and spinal cord ependymoma (n = 1)], and two patients treated at 35 mg/m 2 (MEN2b and metastatic medullary carcinoma of the thyroid, and one patient with metastatic hepatocellular carcinoma) had stable disease for 19, 9, 2, and 8 months, respectively. The last patient came off the study at 8 months on the basis of quality-of-life considerations.
Pharmacokinetics PK parameters were available from cycle 1 in five patients and from cycle 5 in three patients ( and did not receive cycle 5 PK as a result of stopping treatment secondary to a DLT. Of the two patients who received 60 mg/m 2 in cycle 1, the median C max was 1215 ng/ml, whereas the three patients who received 35 mg/m 2 in cycle 1 had a median C max of 790 mg/m 2 . The median C max reported previously for 13 patients on Tem 25 and 75 mg/m 2 without VPA was 448 and 442 ng/ml, respectively. The C max for our patients who had received 35 mg/m 2 in cycle 1 ranged from 649 to 1260 ng/ml, averaging twice the C max observed at even the 75 mg/m 2 dose level in patients without VPA.
Histone acetylation measurements
As a marker of HDAC activity, we examined histone H4 acetylation in PBMCs isolated from three patients for whom there were adequate samples that represented pretreatment as well as after the initiation of VPA and after both VPA and Tem. For two of these patients, we observed a significant increase in histone acetylation after treatment with both VPA and Tem, but not VPA only ( Fig. 1a and b) . The one patient for whom histone acetylation was not increased had a low VPA level. As VPA doses were adjusted during the initiation of Tem, data from patient no. 6 suggest that the dose of VPA determines histone acetylation, and that plasma levels of greater than 70 mcg/dl are required to inhibit HDAC activity in PBMC (Fig. 1c ).
Discussion
In this phase I study, carried out in children and adolescents with refractory pediatric solid tumors, we found that a dose of 35 mg/m 2 of Tem appeared to be well tolerated when the drug was combined with VPA. The premature termination of the study because of slow accrual and the heterogeneous nature of our patient population leave open the possibility that further dose modification might be needed. Nonetheless, the MTD of Tem, when administered with VPA, is clearly significantly lower than the MTD reported in multiple adult trials [1, 8, 9] and in a recent phase I pediatric study of Tem alone (150 mg/m 2 ) [13] . However, it is well above the 10 mg/m 2 dose identified by those researchers as inducing a complete response in a child with multiply relapsed neuroblastoma. Previous researchers have shown that doses of Tem as low as 25 mg inhibit mTOR activity and no relationship has been identified between the dose of Tem and the degree of mTOR inhibition [1] . The frequent occurrence of dose-limiting mucositis in our study contrasts strikingly with the previously published phase I trial of Tem as a single agent [13] , and suggests that VPA might increase the mucosal toxicity of Tem. It is noteworthy that several patients who continued for many months on study or off study at lower doses and every other week for prolonged periods after the initial 6 weeks experienced additional side effects, justifying prolonged monitoring of patients on Tem.
Most of our patients experienced some amount of fatigue. We attributed this effect to VPA as this was often noted before the initiation of Tem and is a known effect of VPA [16, 23] . Interference with activities of daily living during the first few weeks of combination therapy required dose reduction of VPA. Serum levels often decreased well below the targeted levels of 75-100 mcg/ml, and somnolence became our dosing endpoint rather than serum levels. However, this seems to have resulted in reduced VPA levels that were not associated with HDAC activity.
Our PK results offer one explanation for the lower MTD for Tem when combined with VPA compared with its MTD as a single agent. Tem C max and AUC in children taking VPA was much higher than reported previously in children taking Tem without VPA [13] . Peak Tem levels in the 60 mg/m 2 dose level at both cycles ranged from 757 to 1220 ng/ml compared with 369-630 ng/ml found in children who had received 75 mg/m 2 Tem in the previous study. The higher C max and greater exposure of Tem at the 60 mg/m 2 dose level may have resulted in DLTs. Interestingly, one patient who discontinued treatment because of dose-limiting mucositis had a C max of 1210 ng/ml during cycle 1, almost three times the C max reported in patients taking Tem 75 mg/m 2 without VPA. VPA is known to be a broad-spectrum metabolic inhibitor, primarily inhibiting CYP2C9, but exerting some competitive inhibitory effects on CYP3A4 [24] ; Tem is primarily metabolized in the liver by CYP3A4 [22] . These data suggest a possible interaction between Tem and VPA resulting in increased concentrations of Tem. Because our patient population was heterogeneous, CYP enzyme polymorphisms may have played a role in variable PK results and how well this drug combination was tolerated.
In a phase I study of VPA alone [16] , increased acetylated H4 was observed in half of the patients associated with levels of 55-100 mcg/ml, although others have suggested that acetylation is not significantly inhibited until levels greater than 100 mcg/ml are achieved [25] . The VPA levels in our patients were quite variable and were below 100 mcg/ml in all patients. Nonetheless, with limited patients, there appeared to be an association between VPA level and histone acetylation, suggesting that Tem might potentiate the affect of VPA on histone acetylation. Additional patients will need to be studied to clarify this interaction. If confirmed, a drug-drug interaction may explain the grade 1 or 2 fatigue, which was observed despite dose reductions and at relatively low plasma levels of VPA. In the present study, we attempted to preserve Tem by reducing VPA doses. However, this strategy seems to have reduced HDAC activity, which could have compromised the biological synergy predicted in vitro for combined VPA and Tem treatment. Our MTD of 35 mg/ m 2 /week was met when VPA doses were decreased, using fatigue rather than serum levels as the eventual endpoint.
Reduced Tem MTD has also been associated with combination treatment with metformin [26] . Together, these studies suggest that Tem, when administered in combination with other agents, may show a unique toxicity profile justifying study-based evaluation.
Because this was designed as a phase I and not a phase II trial, and because of the heterogeneous diagnoses of participating individuals, response data were inconclusive. However, an objective response -although not fulfilling the RECIST criteria for partial response -was Increased histone acetylation was associated with Tem and VPA treatment. (a) Extracts of purified peripheral blood mononuclear cells were immunoblotted for tetra-acetyl H4 and total H4. A representative blot is shown (b, c). Histone acetylation increased after both Tem and VPA treatment in two of three assayable patients. The signal from H4-Ac relative to pan-H4±SEM is shown. Relative acetylation corresponded with the VPA levels (shown above bars), and the levels of greater than 70 mcg/dl appear to be required to inhibit histone deacetylase activity in peripheral blood mononuclear cells. Tem, temsirolimus; VPA, valproic acid.
observed in one individual with disseminated melanoma. To what extent response was because of the combination rather than single-agent activity is not clear from this single-arm trial. Lesser responses were observed in children with other diagnoses for which there have been few therapeutic options. Response was not predicted in this small series by mTORC1 and mTORC2 staining, which were convincingly expressed in all pretreatment tumor samples.
The combination of Tem and VPA merits further study and may have activity in melanoma. Attention to drugdrug interactions will be important in future multiagent trials including Tem. Additional attention should be paid in managing the side effects that might be specific to combination agent therapy to maintain the intended biologic effects without significantly compromising quality of life. Phase II trials for diseases such as melanoma for which there are limited single-agent data may need to include two arms to compare the efficacy of combination therapy with single-agent treatment. Because of concerns about compliance, we remain enthusiastic about the intravenous administration of mTOR inhibitors for future studies.
